文献速递乳腺MR

MRI影像组学评估乳腺癌新辅助化疗患者的分子亚型、病理完全缓解与残余肿瘤负荷

MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
PubMed 文献 · Acad Radiol · 2020-11-05

该回顾性研究纳入2009年9月至2016年7月间接受新辅助化疗的259例单侧乳腺癌患者,提取治疗前MRI影像组学特征,分析其与分子亚型、病理完全缓解及残余肿瘤负荷的关联。结果显示多种形态学与纹理特征与分子亚型、pCR及RCB相关,其中SSF=6 mm的强度标准差在TNBC中预测pCR的AUC最高(0.734)。作者认为这些特征可能作为无创影像生物标志物用于识别肿瘤亚型并预测新辅助化疗反应。

要点

  • 治疗前MRI影像组学特征与乳腺癌分子亚型相关,肿瘤体积、最长轴径及最长容积径在亚型间差异显著。
  • HER2+肿瘤中球形度与pCR显著相关,luminal肿瘤中SSF=2、4、6 mm的熵与pCR显著相关。
  • TNBC中SSF=6 mm的强度标准差预测pCR的AUC最高(0.734),多个特征与pCR及RCB显著相关。

核心结论

  • MRI影像组学特征与乳腺癌不同分子亚型、病理完全缓解及残余肿瘤负荷相关,可能作为无创影像生物标志物用于识别肿瘤亚型并预测新辅助化疗反应。

研究设计与样本

  • 回顾性分析经伦理审查委员会批准,纳入2009年9月至2016年7月间接受新辅助化疗的活检证实乳腺癌患者。
  • 共纳入259例单侧乳腺癌患者,其中HER2+ 73例(28.2%)、luminal 112例(43.2%)、三阴性乳腺癌74例(28.6%)。
  • 在第一期增强后图像上手动识别并半自动分割肿瘤,计算形态学及三维纹理特征,包括未滤波和滤波图像数据,空间缩放因子(SSF)为2、4、6 mm。
  • 采用Wilcoxon秩和检验和受试者工作特征曲线下面积进行统计分析。

关键影像表现/征象

  • 肿瘤体积(p=0.008)、最长轴径(p=0.009)及最长容积径(p=0.01)在分子亚型间差异显著。
  • SSF=4 mm时最小信号强度(p=0.009)和熵(p=0.02)在亚型间差异显著;SSF=6 mm时最小信号强度(p=0.007)和熵(p<0.001)在亚型间差异显著。
  • HER2+肿瘤中球形度(p=0.04)与pCR显著相关;luminal肿瘤中SSF=2、4、6 mm的熵(p=0.004、0.02、0.047)与pCR显著相关。

诊断标准与关键数值

  • TNBC中SSF=6 mm的强度标准差预测pCR的AUC最高(AUC=0.734)。
  • TNBC中多个特征与pCR显著相关(p<0.05),luminal肿瘤和TNBC中多个特征与RCB显著相关(p<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: There are limited data on pretreatment imaging features that can predict response to neoadjuvant chemotherapy (NAC). To extract volumetric pretreatment MRI radiomics features and assess corresponding associations with breast cancer molecular subtypes, pathological complete response (pCR), and residual cancer burden (RCB) in patients treated with NAC.

MATERIALS AND METHODS: In this IRB-approved study, clinical and pretreatment MRI data from patients with biopsy-proven breast cancer who received NAC between September 2009 and July 2016 were retrospectively analyzed. Tumors were manually identified and semi-automatically segmented on first postcontrast images. Morphological and three-dimensional textural features were computed, including unfiltered and filtered image data, with spatial scaling factors (SSF) of 2, 4, and 6 mm. Wilcoxon rank-sum tests and area under the receiver operating characteristic curve were used for statistical analysis.

RESULTS: Two hundred and fifty nine patients with unilateral breast cancer, including 73 (28.2%) HER2+, 112 (43.2%) luminal, and 74 (28.6%) triple negative breast cancers (TNBC), were included. There was a significant difference in the median volume (p = 0.008), median longest axial tumor diameter (p = 0.009), and median longest volumetric diameter (p = 0.01) among tumor subtypes. There was also a significant difference in minimum signal intensity and entropy among the tumor subtypes with SSF = 4 mm (p = 0.009 and p = 0.02 respectively) and SSF = 6 mm (p = 0.007 and p < 0.001 respectively). Additionally, sphericity (p = 0.04) in HER2+ tumors and entropy with SSF = 2, 4, 6 mm (p = 0.004, 0.02, 0.047 respectively) in luminal tumors were significantly associated with pCR. Multiple features demonstrated significant association (p < 0.05) with pCR in TNBC and with RCB in luminal tumors and TNBC, with standard deviation of intensity with SSF = 6 mm achieving the highest AUC (AUC = 0.734) for pCR in TNBC.

CONCLUSION: MRI radiomics features are associated with different molecular subtypes of breast cancer, pCR, and RCB. These features may be noninvasive imaging biomarkers to identify cancer subtype and predict response to NAC.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Choudhery S, Gomez-Cardona D, Favazza CP, et al. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. Acad Radiol. 2020. PMID: 33160859. doi:10.1016/j.acra.2020.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。